查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613256

巨细胞病毒治疗的全球市场（按疾病、药物、通路和应用）：未来预测（2025-2030）

Cytomegalovirus Treatment Market by Diseases (Encephalitis, Gastrointestinal Ulcers, Pneumonia), Drug (Cidofovir, Foscarnet, Ganciclovir), Distribution Channel, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年巨细胞病毒治疗市值为5.3844亿美元，预计到2024年将达到5.7699亿美元，复合年增长率为7.67%，到2030年将达到9.0339亿美元。

巨细胞病毒(CMV) 疗法是感染疾病治疗市场的重要组成部分，主要集中在治疗影响免疫力缺乏患者的 CMV感染疾病，例如器官移植患者和 HIV 感染者。市场范围已从抗病毒药物和生物疗法扩展到CMV疫苗和免疫疗法等新型治疗方法，而CMV的显着发病率和严重併发症的可能性导致了全面的解决方案的迫切需求。 CMV 疗法具有广泛的用途，包括医疗设施、研究机构和製药公司，展示了广泛的最终用途。市场洞察表明，由于 CMV 感染率上升、新疗法研发的进步以及医疗保健成本上升，成长正在加速。此外，对生物製药创新的大力投资以及政府对 CMV 药物开发的支持正在加速市场开拓。最新的机会在于开发新型抗病毒药物、创新疫苗配方以及具有更高功效和安全性的下一代免疫疗法。生技公司和研究机构之间的策略联盟可以加速产品开发和市场开拓。然而，限制因素包括药品成本上升、抗药性的可能性以及减缓新产品核准的监管障碍。应对这些挑战需要对先进研究进行大量投资，特别是寻找有潜力带来突破性治疗药物方法的基因疗法和病原体特异性药物。此外，新兴市场的经济限制和意识低是实现最佳市场渗透的主要障碍。为了促进创新，应优先考虑个人化医疗和先进基因组技术的研究，以提高治疗的特异性和患者的治疗结果。在科学进步和未满足的临床需求的推动下，CMV 治疗市场的性质不断变化，需要持续洞察趋势和策略敏捷性以抓住新机会。适应技术进步和促进协作对于在这个不断变化的环境中实现持续成长和领导地位至关重要。

主要市场统计
基准年[2023] 53844万美元
预测年份 [2024] 57699万美元
预测年份 [2030] 90339万美元
复合年增长率（%） 7.67%

市场动态：快速发展的巨细胞病毒治疗市场的关键市场洞察

巨细胞病毒治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 巨细胞病毒感染盛行率增加
    • 随着医疗费用的增加，人们对 CMV 及其影响的认识不断提高
  • 市场限制因素
    • 药品成本上升和商业化的限制
  • 市场机会
    • CMV诊断与治疗药物技术进展
    • 增加对卫生基础设施的投资，以改善获得先进 CMV 治疗的机会
  • 市场挑战
    • CMV 药物开发中的监管和标准化挑战

波特五力：驾驭巨细胞病毒治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。它为评估公司的竞争力和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解巨细胞病毒治疗市场的外部影响

外部宏观环境因素在塑造巨细胞病毒治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解巨细胞病毒治疗药物市场的竞争格局

对巨细胞病毒治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：巨细胞病毒治疗市场供应商的绩效评估

FPNV定位矩阵是评估巨细胞病毒治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製巨细胞病毒治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对巨细胞病毒病毒治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析最近的产品发布、开拓的地区、关键产业进展以及塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1. 目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 哪些收益来源和策略机会推动供应商的进入/退出策略？

目录

第一章简介

第二章 分析方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 巨细胞病毒感染的传播
      • 提高对 CMV 及其影响的认识并增加医疗费用
    • 抑制因素
      • 药品成本高且商业化受到限制
    • 机会
      • CMV诊断与治疗药物技术进展
      • 增加对卫生基础设施的投资，以改善获得先进 CMV 治疗的机会
    • 任务
      • CMV 药物开发中的监管和标准化挑战
  • 市场区隔分析
    • 药物：治疗巨细胞病毒主要药物更昔洛韦的使用增加
    • 分销管道：透过提供个人化指导和频繁给药，扩大医院药房获得 CMV 药物的机会
  • 波特五力分析
  • PESTEL分析
    • 政治因素
    • 经济因素
    • 社会因素
    • 技术因素
    • 法律因素
    • 环境因素

第六章巨细胞病毒治疗药物市场：依疾病分类

  • 脑炎
  • 胃肠道溃疡
  • 肺炎
  • 视网膜炎

第七章巨细胞病毒治疗药物市场：依药物分类

  • 西多福韦
  • 膦甲酸
  • 更昔洛韦
  • 缬更昔洛韦

第八章巨细胞病毒治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章巨细胞病毒治疗药物市场：依应用分类

  • 先天性鉅细胞病毒感染疾病
  • 器官移植
  • 干细胞移植

第10章美洲巨细胞病毒治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太鉅巨细胞病毒治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲巨细胞病毒治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • Livtencity，移植后巨细胞病毒感染的新疗法在中国核准
    • 默克公司的 PREVYMIS 获得 CHMP核准，用于在肾臟和干细胞移植患者中扩大 CMV 预防
    • 美国市售的 Kamata CYTOGAM 功能增强和肺移植中 CMV 预防的显着临床资料
  • 战略分析和建议

公司名单

  • Aetos Pharma Private Limited
  • Ajanta Pharma Ltd.
  • Cipla Limited
  • Emcure Pharmaceuticals Limited
  • Exela Pharma Sciences, LLC
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • LEXICARE PHARMA PVT. LTD.
  • Merck & Co., Inc
  • Rakshit Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma
  • Xediton Pharmaceuticals Inc.
Product Code: MRR-7949F05839D1

The Cytomegalovirus Treatment Market was valued at USD 538.44 million in 2023, expected to reach USD 576.99 million in 2024, and is projected to grow at a CAGR of 7.67%, to USD 903.39 million by 2030.

Cytomegalovirus (CMV) treatment is a critical segment of the infectious disease therapeutics market, focusing on managing CMV infections, primarily affecting immunocompromised patients, such as organ transplant recipients and those with HIV. The market scope extends from antiviral drugs and biologic therapies to novel treatment approaches like CMV vaccines and immunotherapy, highlighting a pressing necessity for comprehensive solutions owing to CMV's significant morbidity and potential for severe complications. The application of CMV treatment spans healthcare facilities, research institutes, and pharmaceutical companies, underlining a broad end-use scope. Market insights suggest accelerated growth driven by rising CMV infection rates, advancing R&D for newer treatment modalities, and increasing healthcare expenditure. Additionally, robust investments in biopharmaceutical innovations and government support for CMV drug development amplify market expansion. The latest opportunities lie in the development of novel antivirals with improved efficacy and safety profiles, innovative vaccine formulations, and next-generation immunotherapies. Strategic collaborations between biotech firms and research entities could expedite product development and market entry. However, limitations include high treatment costs, potential drug resistance, and regulatory hurdles slowing new product approvals. Addressing these challenges requires focused investment in advanced research, particularly exploring genetic therapies and pathogen-specific drugs that could lead to breakthroughs. Furthermore, economic constraints and limited awareness in developing regions pose significant barriers to optimal market penetration. To spur innovation, research into personalized medicine and advanced genomic technologies should be prioritized, aimed at enhancing treatment specificity and patient outcomes. The nature of the CMV treatment market is dynamic, driven by scientific advances and unmet clinical needs, necessitating continuous monitoring of trends and strategic agility to capture emerging opportunities. Adapting to technological advancements and fostering collaborations will be pivotal for sustained growth and leadership within this evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 538.44 million
Estimated Year [2024] USD 576.99 million
Forecast Year [2030] USD 903.39 million
CAGR (%) 7.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cytomegalovirus Treatment Market

The Cytomegalovirus Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cytomegalovirus infections
    • Increasing awareness about CMV and its implications, coupled with rising healthcare spending
  • Market Restraints
    • High cost of treatment coupled with limited commercialization
  • Market Opportunities
    • Advancements in CMV diagnosis and treatment technologies
    • Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
  • Market Challenges
    • Regulatory and standardization challenges in CMV treatment development

Porter's Five Forces: A Strategic Tool for Navigating the Cytomegalovirus Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cytomegalovirus Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cytomegalovirus Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cytomegalovirus Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cytomegalovirus Treatment Market

A detailed market share analysis in the Cytomegalovirus Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cytomegalovirus Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cytomegalovirus Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cytomegalovirus Treatment Market

A strategic analysis of the Cytomegalovirus Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetos Pharma Private Limited, Ajanta Pharma Ltd., Cipla Limited, Emcure Pharmaceuticals Limited, Exela Pharma Sciences, LLC, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline PLC, LEXICARE PHARMA PVT. LTD., Merck & Co., Inc, Rakshit Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Weefsel Pharma, and Xediton Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diseases, market is studied across Encephalitis, Gastrointestinal Ulcers, Pneumonia, and Retinitis.
  • Based on Drug, market is studied across Cidofovir, Foscarnet, Ganciclovir, and Valganciclovir.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Application, market is studied across Congenital CMV Infection, Organ Transplantation, and Stem Cell Transplantation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cytomegalovirus infections
      • 5.1.1.2. Increasing awareness about CMV and its implications, coupled with rising healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with limited commercialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in CMV diagnosis and treatment technologies
      • 5.1.3.2. Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and standardization challenges in CMV treatment development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Growing usage of ganciclovir primary medication to treat cytomegalovirus
    • 5.2.2. Distribution Channel: Growing accessibility of CMV treatments across Hospital pharmacies as it provides personal guidance and frequent medication
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cytomegalovirus Treatment Market, by Diseases

  • 6.1. Introduction
  • 6.2. Encephalitis
  • 6.3. Gastrointestinal Ulcers
  • 6.4. Pneumonia
  • 6.5. Retinitis

7. Cytomegalovirus Treatment Market, by Drug

  • 7.1. Introduction
  • 7.2. Cidofovir
  • 7.3. Foscarnet
  • 7.4. Ganciclovir
  • 7.5. Valganciclovir

8. Cytomegalovirus Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Cytomegalovirus Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Congenital CMV Infection
  • 9.3. Organ Transplantation
  • 9.4. Stem Cell Transplantation

10. Americas Cytomegalovirus Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Approval of LIVTENCITY in China a Novel Treatment for Post-Transplant Cytomegalovirus Infections
    • 13.3.2. Merck's PREVYMIS Gains CHMP Endorsement for Extended CMV Prophylaxis in Kidney and Stem Cell Transplant Recipients
    • 13.3.3. Kamada's CYTOGAM Enhancements in U.S. Commercial Availability and Notable Clinical Data on CMV Prophylaxis in Lung Transplants
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetos Pharma Private Limited
  • 2. Ajanta Pharma Ltd.
  • 3. Cipla Limited
  • 4. Emcure Pharmaceuticals Limited
  • 5. Exela Pharma Sciences, LLC
  • 6. F. Hoffmann-La Roche Ltd
  • 7. Fresenius Kabi AG
  • 8. GlaxoSmithKline PLC
  • 9. LEXICARE PHARMA PVT. LTD.
  • 10. Merck & Co., Inc
  • 11. Rakshit Pharmaceuticals Limited
  • 12. Teva Pharmaceutical Industries Ltd.
  • 13. Weefsel Pharma
  • 14. Xediton Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CYTOMEGALOVIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CYTOMEGALOVIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYTOMEGALOVIRUS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GASTROINTESTINAL ULCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CIDOFOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY VALGANCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CONGENITAL CMV INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. CYTOMEGALOVIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. CYTOMEGALOVIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023